Vera Therapeutics (VERA)
(Delayed Data from NSDQ)
$19.79 USD
+0.07 (0.35%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $19.78 -0.01 (-0.05%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VERA 19.79 +0.07(0.35%)
Will VERA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VERA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VERA
Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet
VERA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for VERA
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VERA Stock News
JP Morgan Adjusts Price Target for Vera Therapeutics (VERA), Maintains Rating | VERA Stock News
Vera Therapeutics GAAP EPS of -$1.20 misses by $0.50
Vera (VERA) Reports Strong Financial Position to Support Future Initiatives
Vera Therapeutics (VERA) Prepares for FDA Approval Following Promising Trial Results